Abstract
Treatment results of human hepatoblastoma (HB) have been improved remarkably during recent years, mainly through the establishment of integrated regimens controlled and coordinated by multicentric treatment studies. Today, neoadjuvant and adjuvant chemotherapy is combined with surgical resection of the tumors. The main therapeutic goal is a complete surgical removal of tumor masses, which is also essential for the survival of the patients. Despite improved overall survival rates, treatment results of advanced tumors are still far from being satisfying. Multidrug resistance has been identified as a major factor responsible for the bad prognosis of children suffering from advanced staged hepatoblastoma. During recent years investigations focused on factors contributing to drug resistance in hepatoblastoma and on possible approaches towards overcoming this therapeutical challenge. Alternative approaches that are currently evaluated in experimental and clinical settings comprise new cytotoxic agents, chemosensitizers, gene directed applications but also surgical techniques and an expansion of indication for liver transplantation.
Keywords: P-Glycoprotein, MDR1 gene expression, Glutathione S-Transferase Micro, chemoresistance, Bcl-2 gene, TOPO II enzyme
Current Pharmaceutical Biotechnology
Title: Drug Resistance in Hepatoblastoma
Volume: 8 Issue: 2
Author(s): S. W. Warmann and J. Fuchs
Affiliation:
Keywords: P-Glycoprotein, MDR1 gene expression, Glutathione S-Transferase Micro, chemoresistance, Bcl-2 gene, TOPO II enzyme
Abstract: Treatment results of human hepatoblastoma (HB) have been improved remarkably during recent years, mainly through the establishment of integrated regimens controlled and coordinated by multicentric treatment studies. Today, neoadjuvant and adjuvant chemotherapy is combined with surgical resection of the tumors. The main therapeutic goal is a complete surgical removal of tumor masses, which is also essential for the survival of the patients. Despite improved overall survival rates, treatment results of advanced tumors are still far from being satisfying. Multidrug resistance has been identified as a major factor responsible for the bad prognosis of children suffering from advanced staged hepatoblastoma. During recent years investigations focused on factors contributing to drug resistance in hepatoblastoma and on possible approaches towards overcoming this therapeutical challenge. Alternative approaches that are currently evaluated in experimental and clinical settings comprise new cytotoxic agents, chemosensitizers, gene directed applications but also surgical techniques and an expansion of indication for liver transplantation.
Export Options
About this article
Cite this article as:
Warmann W. S. and Fuchs J., Drug Resistance in Hepatoblastoma, Current Pharmaceutical Biotechnology 2007; 8 (2) . https://dx.doi.org/10.2174/138920107780487456
DOI https://dx.doi.org/10.2174/138920107780487456 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Concomitant Expression of Inhibitory Molecules for T cell Activation Predicts Poor Survival in Patients with Esophageal Squamous Cell Carcinoma
Current Cancer Drug Targets Development of Curcumin-Loaded Solid Lipid Nanoparticles Utilizing Glyceryl Monostearate as Single Lipid Using QbD Approach: Characterization and Evaluation of Anticancer Activity Against Human Breast Cancer Cell Line
Current Drug Delivery BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design The Use of Herbal Medicine in Cancer-related Anorexia/ Cachexia Treatment Around the World
Current Pharmaceutical Design Obesity-Driven Inflammation and Colorectal Cancer
Current Medicinal Chemistry Osteoprotegerin A Physiological and Pharmacological Inhibitor of Bone Resorption.
Current Pharmaceutical Design HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment
Current Cancer Therapy Reviews Unique Coronary Artery Disease Differences in Women as Related to Revascularization
Current Medicinal Chemistry MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Part II: Targeted Particles for Imaging of Anticancer Immune Responses
Current Drug Delivery Therapeutic Enhancement of IL-2 Through Molecular Design
Current Pharmaceutical Design Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia
Current Pharmaceutical Design The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Bioactive Compounds Isolated from Defatted Microalgal Biomasses of <i>Botryococcus Braunii</i> and <i>Dunaliella Tertiolecta</i> showing a Tyrosinase Inhibitory Activity
Current Bioactive Compounds Uncovering the Diversification of Tissue Engineering on the Emergent Areas of Stem Cells, Nanotechnology and Biomaterials
Current Stem Cell Research & Therapy Tachykinins and their Receptors in Human Malignancies
Current Drug Targets Targeted α-Particle Therapy: A Clinical Overview
Current Radiopharmaceuticals Gold Nanoparticles by Laser Ablation for X-Ray Imaging and Protontherapy Improvements
Recent Patents on Nanotechnology